BRCA1 and cancer: Conversely, pharmacological activation of TET enzymes using Vitamin C leading to global increase in 5hmC levels can exacerbate PARP trapping at sites of DNA damage, effectively restoring sensitivity to PARPi in chemoresistant cancer cells, particularly those harboring BRCA1 or BRCA2 deficiencies.